Skip to search formSkip to main contentSkip to account menu

Afatinib 40 MG Oral Tablet [Gilotrif]

Known as: Gilotrif 40 MG (as afatinib dimaleate 59.12 MG) Oral Tablet, Gilotrif 40 MG Oral Tablet, afatinib 40 mg ORAL TABLET, FILM COATED [Gilotrif] 
National Institutes of Health

Related topics

Related topics

3 relations
AfatinibOral Tablet

Broader (1)

Afatinib 40 MG Oral Tablet

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Budget impact of sequential treatment with first-line afatinib versus first-line osimertinib in non-small-cell lung cancer patients with common EGFR mutations
Background The therapeutic landscape for non-small-cell lung cancer (NSCLC) patients that have common epidermal growth factor… 
2018
2018
Afatinib in advanced NSCLC: a profile of its use
Afatinib [Giotrif® (EU); Gilotrif® (USA)] is an orally administered, irreversible inhibitor of the ErbB family of tyrosine… 
2017
2017
Chinese Medicine Treatment for Afatinib-Induced Paronychia
Afatinib (Gilotrif™) is widely used to treat patients with mutant activating epidermal growth factor receptor- (EGFR-) dependent… 
Review
2016
Review
2016
Afatinib: A Review in Advanced Non-Small Cell Lung Cancer
Afatinib (Giotrif®, Gilotrif®) is an orally administered, irreversible inhibitor of the ErbB family of tyrosine kinases. In the… 
2016
2016
Abstract 4814: miRNA combination therapy:In vitroanticancer synergy between miR-34a mimic and next generation EGFR tyrosine kinase inhibitors (TKIs) in NSCLC
Background: miRNAs play a critical role in regulating key biological processes by modulating the expression of up to several… 
2016
2016
The Score Card Approach: A First Step Toward an Evidence-based Differentiation Assessment for Tablets
Background The differentiation of tablets by their physical appearance is a contributing factor to the safe use of medications… 
Review
2014
Review
2014
Afatinib: A Review of Its Use in the Treatment of Advanced Non-Small Cell Lung Cancer
Afatinib (Gilotrif™, Giotrif®) is an orally administered, irreversible inhibitor of the ErbB family of tyrosine kinases. Afatinib… 
2014
2014
The Symptom Experience of Patients Receiving Epidermal Growth Factor Receptor Inhibitors
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)